High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study

Paul Welsh1, Olia Papacosta2, Sheena Ramsay3

  • 1BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.

Insights

High-sensitivity troponin T (hsTnT) is linked to heart failure (HF) risk in older men. However, hsTnT does not enhance HF prediction when N-terminal pro-B-type natriuretic peptide is already included.

Area of Science:

  • Cardiology
  • Biomarkers
  • Epidemiology

Background:

  • Heart failure (HF) is a significant public health concern.
  • Biomarkers like high-sensitivity troponin T (hsTnT) are being investigated for their role in predicting cardiovascular events.
  • Understanding the predictive value of hsTnT for incident HF is crucial for refining risk assessment strategies.

Purpose of the Study:

  • To investigate the association between hsTnT levels and the incidence of HF in older men.
  • To evaluate the added value of hsTnT in HF prediction models, particularly when N-terminal pro-B-type natriuretic peptide (NT-proBNP) is already considered.

Main Methods:

  • The British Regional Heart Study cohort, comprising 3852 men aged 60-79 years without baseline HF, was followed for a median of 12.6 years.
  • Incident HF cases were identified, and the association between hsTnT and HF risk was analyzed using Cox proportional hazards models, adjusting for traditional risk factors and NT-proBNP.
  • The predictive performance of risk models with and without hsTnT was assessed using the C-index.

Main Results:

  • A 1-SD increase in hsTnT was associated with a 58% higher risk of incident HF (HR 1.58) after adjusting for classic risk factors, and a 34% higher risk after further adjustment for NT-proBNP (HR 1.34).
  • The predictive value of hsTnT did not vary across different risk factor strata.
  • While a low hsTnT (<5ng/L) showed high sensitivity for ruling out HF, adding hsTnT to a model with NT-proBNP did not significantly improve HF prediction (P = 0.28).

Conclusions:

  • Elevated hsTnT is consistently associated with an increased risk of incident HF in older men.
  • HF incidence was low in men with hsTnT below the limit of detection.
  • hsTnT measurement does not improve HF prediction when NT-proBNP is already incorporated into the risk model.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
964
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
987
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330